|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2000-9-19
|
|
pubmed:abstractText |
Doxil (ALZA Corp., Mountain View, CA) is a formulation of doxorubicin in polyethylene-glycol coated liposomes with a prolonged circulation time and unique toxicity profile. As yet, the effect of the dose schedule on toxicity and the correlation of toxicity with pharmacokinetics have not been directly addressed.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
89
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1037-47
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10964334-Adult,
pubmed-meshheading:10964334-Aged,
pubmed-meshheading:10964334-Antineoplastic Agents,
pubmed-meshheading:10964334-Breast Neoplasms,
pubmed-meshheading:10964334-Doxorubicin,
pubmed-meshheading:10964334-Drug Administration Schedule,
pubmed-meshheading:10964334-Drug Carriers,
pubmed-meshheading:10964334-Drug Delivery Systems,
pubmed-meshheading:10964334-Female,
pubmed-meshheading:10964334-Humans,
pubmed-meshheading:10964334-Liposomes,
pubmed-meshheading:10964334-Middle Aged,
pubmed-meshheading:10964334-Neoplasm Metastasis,
pubmed-meshheading:10964334-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
|
|
pubmed:affiliation |
Sharet Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
